Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs

Abstract

1 The multiple dose pharmacokinetics of pegylated liposomal doxorubicin (PL-DOX), known as DOXIL® (US) and CAELYX® (EU), was characterized in dogs and a pharmacokinetic/pharmacodynamic model to identify a relationship between drug exposure and the probability of observing treatment-related palmarplantar erythrodysesthesia (PPE) was developed.

2 Twenty dogs were assigned to PL-DOX groups (2/sex/ group) that received intravenous PL-DOX doses of 0.5 mg/kg q1, 2, or 4 weeks; 1.0 mg/kg q2weeks; or 1.5 mg/kg q4weeks for 12 weeks. Blood was collected for HPLC analysis of doxorubicin concentration pre-dose and periodically up to 120 h after dosing three times during treatment.

3 Plasma drug concentration was modeled using iterative 2-stage analysis. Dermal lesions (PPE) were scored twice weekly for six regions of each dog using a 0-6 severity scale; maximum severity was 36. PPE score data were modeled using an approach in which the% probability of PPE was related to a hypothetical effect site by a series of Hill-type functions.

4 Pharmacokinetics were best modeled as a one-compartment open model. Vss (ml/kg), CLt (ml/hr/kg) and half-life (h) were 44.1, 1.39 and 23.1, respectively. Cmax increased linearly with dose. CLt decreased with repeated doses.

5 A two-compartment pharmacodynamic model, which correctly predicted 97% of the observed lesion severity, was developed to establish the relationship of lesion severity to dose intensity (a measure of drug exposure incorporating the effect of both dose level and dosing frequency, which can be expressed in units of mg/kg/week). The model demonstrated that maximal PPE was positively correlated with dose intensity, the major factor that affects the incidence and severity of dermal lesions.

6 The model can be used to predict acceptable dose intensities in humans utilizing body surface area conversion factors and comparative AUCs for dogs and humans. It predicts that a dose intensity of 10-12.5 mg/m² of PL-DOX will be well tolerated in patients. The results of recent clinical studies are consistent with this prediction.

Keywords

CAELYX®DOXIL®pegylated liposomal doxorubicin palmar-plantar erythrodysesthia

References

Working PK et al. Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in Stealth liposomes (DOXIL) . Journal of Liposome Research 1994; 4: 667-687 .

Northfelt DW et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma . Journal of Clinical Pharmacology 1996; 36: 55-63 .

Huang SK et al. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma . Cancer Research 1992; 52: 6774-6781 .

Vaage J , Donovan D , Uster P , Working P. Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma . British Journal of Cancer 1997; 75: 482-486 .

Vaage J et al. Tissue distributions and therapeutic effects of intravenous free or encapsulated liposomal doxorubicin on human prostatic carcinoma xenografts . Cancer 1994; 73: 1478-1484 .

Huang SK et al. Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene . American Journal of Pathology 1994; 143: 10-14 .

Working PK , Dayan AD. Pharmacologicaltoxicological Expert Report. CAELYX (Stealth liposomal doxorubicin HCl) . Human and Experimental Toxicology 1996; 15: 752-785 .

Lokich JJ , Moore C. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome . Annals of Internal Medicine 1984; 101: 798-799 .

Comandone A et al. Palmar-plantar erythrodysesthia syndrome associated with 5- fluorouracil treatment . Anticancer Research 1993; 13: 1781-1783 .

10.

Samuels BL , Vogelzang NJ , Ruane M , Simon MA. Continuous venous infusion of doxorubicin in advanced sarcomas . Cancer Treatment Reports 1987; 71: 971-972 .

11.

Smith IE et al. High complete remission rates with primary neoadjuvant infusional chemotherapy . Journal of Clinical Oncology 1995; 13: 424-429 .

12.

Matsuyama JR , Kwok KK. A variant of the chemotherapy-associated erythrodysesthesia syndrome related to high-dose cyclophosphamide . Drug Intelligence and Clinical Pharmacology 1989; 23: 776, 778-779 .

13.

Vukelja SJ et al. Pyridoxine therapy for palmarplantar erythrodysesthesia associated with taxotere [letter] . Journal of the National Cancer Institute 1993; 85: 1432-1433 .

14.

Gordon KB et al. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy . Cancer 1995; 75: 2169-2173 .

15.

Muggia FM et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation . Journal of Clinical Oncology 1997; 15: 987-993 .

16.

Ranson M et al. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial . Journal of Clinical Oncology 1997; 15: 3185-3191 .

17.

Jucgla A , Sais G. Diagnosis in oncology. Hand-foot syndrome . Journal of Clinical Oncology 1997; 15: 3164-3164 .

18.

Newman MS , Sullivan T , Amantea MA , Working PK. Dermal toxicity associated with pegylated liposomal doxorubicin (DOXIL) in dogs . The Toxicologist 1996; 30: 103-103 .

19.

Prevost G. Estimation of normal probability density function from samples measured with nonnegligible and non-constant dispersion (internal report) Adersa Gerbios, Palaiseau, France , 1977.

20.

Sheiner LB. The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods . Drug Metabolism Reviews 1984; 15: 153-171 .

21.

Steimer JL , Mallet A , Golmard J , Boisieux J. Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed effect model . Drug Metabolism Reviews 1984; 15: 265-292 .

22.

D'Argenio DZ , Schumitzky A. A program package for stimulation and parameter estimation in pharmacokinetic systems . Comparative Progress in Biomedicine 1979; 9: 115-134 .

23.

D'Argenio DZ , Schumitzky A. ADAPT Users Guide (Biomedical Simulations Resource), UCLA, Los Angeles , 1992.

24.

Jusko WJ. Guidelines for collection and analysis of pharmacokinetic data in Applied Pharmacokinetics. In: Principles of Therapeutic Drug Monitoring, Evans WE , Jusko J , Schentag JJ , (eds.) 1-43 Vancouver, WA, Applied Therapeutics, Inc. , 1992.

25.

Akaike H. Bayesian extension of the minimum AIC procedure of autoregressive model fitting . Biometika 1979; 66: 237-242 .

26.

Hill AV. The possible effects of aggregation of the molecules of haemoglobin on its dissociation curves . Journal of Physiology (London) 1910; 40: IV-VII .

27.

Gabizon A , Barenholz Y , Bialer M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol derivatized phospholipid: pharmacokinetic studies in rodents and dogs . Pharmaceutical Research 1993; 10: 703-708 .

28.

Vukelja SJ , Lombardo FA , James WD , Weiss RB. Pyridoxine for the palmar-plantar erythrodysesthesia syndrome [letter] [published erratum appears in Ann Intern Med 1990 Jan 15; 112(2):151] . Annals of Internal Medicine 1989; 111: 688-689 .

29.

Zimmerman GC et al. Prevention of docetaxel-induced erythrodysesthesia with local hypothermia . Journal of the National Cancer Institute 1994; 86: 557-558 .

30.

Vail DM et al. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin-containing pegylated (Stealth) liposomes: A randomized, double-blind clinical trial using a canine model . Clinical Cancer Research 1998; 4: 1567-1571 .

31.

Amantea MA , Forrest A , Northfelt DW , Mamelok RD. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma . Clinical Pharmacology and Therapeutics 1997; 61: 301-311 .

32.

Freireich EJ et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man . Cancer Chemotherapy Reports 1966; 50: 219-244 .